HCPCS Level II code J1301 identifies one milligram of edaravone administered as an injectable drug. Edaravone is used in specific neurologic indications and is typically delivered in outpatient infusion centers, hospital outpatient departments, or specialty clinics. Accurate coding of J1301 matters nationally because it supports billing for high-cost specialty therapies, ensures consistent drug unit reporting across payers, and affects clinical documentation and reimbursement processes for infusion services.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coding practice for J1301, typical sites of service, common modifiers used in practice (listed elsewhere in the full publication), and payer coverage considerations. The publication summarizes available benchmarks and policy updates relevant to injectable specialty drugs, clarifies clinical context for edaravone administration, and outlines areas where billing clarity is commonly needed.

This national-level summary is intended to help billing, compliance, and clinical teams understand the role of HCPCS Level II code J1301 in specialty infusion billing, payer interactions, and clinical documentation workflows. Data not available in the input.